Is TKMR a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

314 people get TKMR articles and Market Currents by email alert.

Get email alerts on TKMR »

HEADLINES:

Tekmira Announces Election of Directors

GlobeNewswire (Fri, 6:15PM)
Tekmira Presents LNP Technology Innovations at Scientific Symposium

GlobeNewswire (May 15, 2013)
Tekmira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 14
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial Results

GlobeNewswire (May 9, 2013)
Tekmira Provides Update on U.S. Government Sponsored TKM-Ebola Program

GlobeNewswire (May 8, 2013)
The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapy
PropThink • Tue, Apr 23 • 1 Comment
Early-Stage Clinical Data Highlights From AACR 2013
Brian L. Wilson • Wed, Apr 17
Tekmira's TKM-PLK1 Is Promising For Solid Tumors
Grant Zeng • Wed, Apr 10 • 2 Comments
Tekmira's Collaborators at the National Cancer Institute Present Preclinical Data at the Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire (Apr 10, 2013)
Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting

GlobeNewswire (Apr 9, 2013)
Biotechs With Staggering Potential: Grant Zeng
Life Sciences Report • Fri, Apr 5 • 5 Comments
Promising RNA Company Tekmira Ready To Release Data At AACR 2013
Brian L. Wilson • Tue, Apr 2 • 2 Comments
Tekmira Provides Corporate Update and Announces Year-End Audited 2012 Results

GlobeNewswire (Mar 27, 2013)
Tekmira: An Undervalued Pioneer In The Field Of RNAi Therapeutics
Grant Zeng • Thu, Mar 21 • 6 Comments
Tekmira Conference Call and Webcast Advisory: Corporate Update and Year-End 2012 Financial Results

GlobeNewswire (Mar 20, 2013)
Biotech Bubble: Alnylam Triples Despite Setbacks And Insider Selling
Richard Pearson • Mon, Feb 25 • 4 Comments
Tekmira Outlines Key 2013 Product Development and Corporate Milestones

GlobeNewswire (Feb 12, 2013)
Tekmira to Webcast Presentation at 15th Annual BIO CEO & Investor Conference

GlobeNewswire (Feb 6, 2013)
Tekmira to Present TKM-PLK1 Phase 1 Clinical Trial Results at AACR

GlobeNewswire (Feb 4, 2013)
With The RNAi Sector Heating Up Again This Is Now The Undervalued Biotech Stock To Watch
M. E. Garza • Fri, Feb 1 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapy
PropThink • Tue, Apr 23 • 1 Comment
Tekmira's TKM-PLK1 Is Promising For Solid Tumors
Grant Zeng • Wed, Apr 10 • 2 Comments
Promising RNA Company Tekmira Ready To Release Data At AACR 2013
Brian L. Wilson • Tue, Apr 2 • 2 Comments
Tekmira: An Undervalued Pioneer In The Field Of RNAi Therapeutics
Grant Zeng • Thu, Mar 21 • 6 Comments
With The RNAi Sector Heating Up Again This Is Now The Undervalued Biotech Stock To Watch
M. E. Garza • Fri, Feb 1 • 1 Comment
Tekmira Could Offer Stockholders Huge Rewards
C.R. Jackson • Thu, Nov 15, 2012 • 1 Comment
Positive FDA Recommendation For Drug Good News For Tekmira
Dan Lukehart • Thu, Mar 22, 2012 • 12 Comments
Tekmira: RNAi Company With Long-Term Potential, Short-Term Catalysts
Dan Lukehart • Wed, Mar 7, 2012 • 12 Comments

Early-Stage Clinical Data Highlights From AACR 2013
Brian L. Wilson • Wed, Apr 17
Biotechs With Staggering Potential: Grant Zeng
Life Sciences Report • Fri, Apr 5 • 5 Comments
Biotech Bubble: Alnylam Triples Despite Setbacks And Insider Selling
Richard Pearson • Mon, Feb 25 • 4 Comments
Applying The Venture Capital Model To Public Companies: Hugh Cleland
Life Sciences Report • Wed, Nov 21, 2012 • 2 Comments
Future Trends In RNAi Drug Delivery
Dan Lukehart • Wed, Mar 28, 2012 • 8 Comments
What Alnylam Doesn't Want You To Know
Dan Lukehart • Fri, Mar 16, 2012 • 8 Comments
Galena Investors Are A Strange Brew
Dan Lukehart • Wed, Mar 7, 2012 • 18 Comments
Alnylam Looks Nearly Left For Dead
Stephen Simpson • Thu, Dec 29, 2011 • 5 Comments

Tekmira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 14

Tekmira Announces Election of Directors

GlobeNewswire (Fri, 6:15PM)
Tekmira Presents LNP Technology Innovations at Scientific Symposium

GlobeNewswire (May 15, 2013)
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial Results

GlobeNewswire (May 9, 2013)
Tekmira Provides Update on U.S. Government Sponsored TKM-Ebola Program

GlobeNewswire (May 8, 2013)
Tekmira's Collaborators at the National Cancer Institute Present Preclinical Data at the Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire (Apr 10, 2013)
Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting

GlobeNewswire (Apr 9, 2013)
Tekmira Provides Corporate Update and Announces Year-End Audited 2012 Results

GlobeNewswire (Mar 27, 2013)
Tekmira Conference Call and Webcast Advisory: Corporate Update and Year-End 2012 Financial Results

GlobeNewswire (Mar 20, 2013)
Tekmira Outlines Key 2013 Product Development and Corporate Milestones

GlobeNewswire (Feb 12, 2013)
Tekmira to Webcast Presentation at 15th Annual BIO CEO & Investor Conference

GlobeNewswire (Feb 6, 2013)
Tekmira to Present TKM-PLK1 Phase 1 Clinical Trial Results at AACR

GlobeNewswire (Feb 4, 2013)
Tekmira's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer Discovery

GlobeNewswire (Jan 31, 2013)
Tekmira Acquires Worldwide License to Novel RNAi Technology

GlobeNewswire (Nov 29, 2012)
Tekmira Provides Corporate Update and Announces Third Quarter 2012 Results

GlobeNewswire (Nov 13, 2012)
Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter 2012 Results

GlobeNewswire (Nov 12, 2012)
Tekmira and Alnylam Restructure Relationship and Settle All Litigation

GlobeNewswire (Nov 12, 2012)
Movers & Shakers: Wednesday’s biggest gaining and declining stocks

at MarketWatch.com (Oct 3, 2012)
Tekmira Provides Update on Collaboration With U.S. Government's TMT Program

GlobeNewswire (Oct 2, 2012)
Tekmira Provides Update on Collaboration With U.S. Government's TMT Program

GlobeNewswire (Sep 27, 2012)
Tekmira Provides Periodic Update to Shareholders Regarding Litigation

GlobeNewswire (Sep 26, 2012)

TKMR vs. ETF Alternatives

Company Description

Currently, there's no company description for TKMR.

Sector: Healthcare

Industry: Diagnostic Substances

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 8:42 AM Tekmira (TKMR) says the Department of Defense has increased funding for the TKM-Ebola program by $6.9M to allow for the integration of "a more potent LNP formulation" and to improve manufacturing technology. The contract with the DOD (now at $41.7M) can be extended up to $140M as needed to get FDA approval. Phase 1 trials should begin ~H2 2013. (PR) Comment! [Healthcare]
Tuesday, November 13, 2012, 10:31 AM Alnylam Pharmaceuticals (ALNY +4.8%) is higher this morning after reaching a settlement with Tekmira Pharmaceuticals (TKMR +19.3%) resolving all litigation issues between the companies. It also signed a new licensing agreement that restructures the relationship and provides clarity on all intellectual property and licensing issues. As a result, TKMR will receive $65M within 10 days and is eligible to receive an additional $10M in near-term milestone payments in 2013. (Conference Call Webcast Replay) Comment! [Healthcare, On the Move]
Wednesday, October 3, 2012, 8:54 AM Tekmira Pharmaceuticals (TKMR) +9.6% after the company said late yesterday that the Department of Defense has lifted a temporary stop-work order on the firm's TKM-Ebola program. Work will now restart on advancing TKM-Ebola under the existing contract. Comment! [Healthcare, On the Move]
Thursday, August 9, 2012, 2:02 PM Tekmira Pharmaceuticals (TKMR +4.9%) gives an update on its leukemia drug Marqibo, saying that its licensing partner, Talon Therapeutics, has received accelerated approval from the FDA for the treatment of adult patients with leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Comment! [Healthcare, On the Move]

Scott Matusow
I bought $TKMR, hearing good stuff, I think it could move nicely
11/7/12
Reply (3)

• !Report Abuse
View all 3 replies
Scott Matusow: short term TKMR
11/8/12
• !Report Abuse
ahw5006: very impressive pick
11/9/12
• !Report Abuse
Add a reply...

140 characters

oncdoc
Hello, anyone invested in this except me. Ive been in since pink sheets. Sure is lonely. Maybe time to buy TKMR is before the hooplah?
8/31/11
Reply (2)

• !Report Abuse
View all 2 replies
oncdoc: anyone? but me?
1/12/12
• !Report Abuse
vastator: This stock has been really good to me with the exception of post-Nasdaq time.. this lawsuit business will surely be interesting..
1/20/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
I bought $TKMR, hearing good stuff, I think it could move nicely
11/7/12
Reply (3)

• !Report Abuse
View all 3 replies
Scott Matusow: short term TKMR
11/8/12
• !Report Abuse
ahw5006: very impressive pick
11/9/12
• !Report Abuse
Add a reply...

140 characters

oncdoc
Hello, anyone invested in this except me. Ive been in since pink sheets. Sure is lonely. Maybe time to buy TKMR is before the hooplah?
8/31/11
Reply (2)

• !Report Abuse
View all 2 replies
oncdoc: anyone? but me?
1/12/12
• !Report Abuse
vastator: This stock has been really good to me with the exception of post-Nasdaq time.. this lawsuit business will surely be interesting..
1/20/12
• !Report Abuse
Add a reply...

140 characters

TKMR Tekmira Pharmaceuticals Corp

TKMR

Tekmira Pharmaceuticals Corp